Skip to main content

Crohn's & Colitis
blogs, news & research

News

Human Body-on-Chip platform enables in vitro prediction of drug behaviors in humans


Fluidically-linked systems of multiple human Organ Chips that quantitatively predict drug pharmacokinetics may offer alternatives to some animal tests.

Drug development is an extremely arduous and costly process, and failure rates in clinical trials that test new drugs for their safety and efficacy in humans remain very high. According to current estimates, only 13.8% of all tested drugs demonstrate ultimate clinical success and obtain approval by the Food and Drug Administration (FDA). There are also increasing ethical concerns relating to the use of animal studies. As a result, there has been a world-wide search to find replacements for animal models.

To help address this bottleneck in drug development, Donald Ingber, M.D., Ph.D., and his team at Harvard’s Wyss Institute for Biologically Inspired Engineering, developed the first human “Organ-on-a-Chip” (Organ Chip) model of the lung that recapitulates human organ level physiology and pathophysiology with high fidelity, which was reported in Science in 2010. Organ Chips are microfluidic culture devices composed of a clear flexible polymer the size of a computer memory stick, which contains two parallel hollow channels that are separated by a porous membrane. Organ-specific cells are cultured on one side of the membrane in one of the channels, and vascular endothelial cells recapitulating a blood vessel line the other, while each channel is independently perfused with cell type-specific medium. The porous membrane allows the two compartments to communicate with each other, and to exchange molecules like cytokines, growth factors, and drugs, as well as drug breakdown products generated by organ-specific metabolic activities.

One example where living animals must be used in preclinical testing is the characterization of a drug’s “pharmacokinetics” (PK) that involves the quantification of its absorption, distribution, metabolism, and excretion (ADME), which together determine drug levels in the blood. These responses involve interplay between many different organs linked by a vasculature containing flowing blood. Animals are also used to analyze drug “pharmacodynamics” (PD), the effects the drug produces on its target organs, which underlies its mechanism of action as well as its adverse effects.

Because the Wyss Institute’s Organ Chips contain an endothelium-lined vascular channel, Ingber proposed in 2011 that it might be possible to create a human “Body-on-Chips” by transferring fluids between the vascular channels of many different types of Organ Chips to mimic blood flow, and assessing drug PK/PD behaviors across the entire linked system. Inspired by this vision and the realization that existing animal-based development programs are inadequate to confront the needs for accelerated development of drug countermeasures in a biothreat situation, the Defense Advanced Research Projects Agency (DARPA) requested grant applications in 2012 with a seemingly impossible challenge: develop 10 types of Organ Chips that recapitulate the complex functionalities of 10 different human organs, engineer an automated instrument to fluidically link them to create a functional human Body-on-Chips platform, and leverage computational modeling in combination with experimental data generated using this platform to quantitatively predict human drug PK/PD behavior in vitro. Now, two back-to-back publications in Nature Biomedical Engineeringdescribe the Wyss team’s success in meeting this goal in full.

“Both studies represent a tremendous effort by scores of researchers at the Wyss Institute, who worked together with our industrial modeling collaborators, and pooled their collective tissue engineering, microfabrication, pharmacological, physiological, and computational expertise to make this huge advance in preclinical drug testing possible,” said Rachelle Prantil-Baun, Ph.D., a Wyss Institute Senior Staff Scientist with past experience in the pharmaceutical industry who helped to orchestrate this complex multi-investigator effort with multiple other staff members in the Wyss’ Bioinspired Therapeutics and Diagnostics platform.

The Interrogator instrument enabled the team to culture, perfuse, and link many living human cultured tissues in a multi-Organ Chip system, as well as add and sample the medium in a fully programmable way, using the device’s robotic liquid transfer capabilities, while continuously monitoring tissue integrity with an integrated microscope. “In this study, we serially linked the vascular channels of eight different Organ Chips, including intestine, liver, kidney, heart, lung, skin, blood–brain barrier and brain, using a highly optimized common blood substitute, while independently perfusing the individual channels lined by organ-specific cells. The instrument maintained the viability of all tissues and their organ-specific functions for over three weeks and, importantly, it allowed us to quantitatively predict the tissue-specific distribution of a chemical across the entire system,” said Richard Novak, Ph.D., a co-first-author on both studies. Novak is a Senior Staff Engineer at the Wyss Institute who designed, fabricated, and operated the Interrogator instrument with his bioengineering team.

In the second study, the team used the Interrogator instrument to support two different configurations of 3 different Organ Chips linked to each other and to a central arterio-venous (AV) fluid mixing reservoir that helped recapitulate life-like blood and drug exchange between the individual organs, while also providing a way to carry out blood sampling that would mimic blood drawing from a peripheral vein. The researchers connected a human Gut Chip, Liver Chip, and Kidney Chip and added nicotine to the Gut Chip’s epithelial channel to simulate oral administration of this drug, and its first passage (first pass) through the intestinal wall into the vascular system that transports it first to the liver where it is metabolized, and further to the kidney where it is excreted. Nicotine chewing gum is used to help with smoking cessation; however, it is also being investigated as an oral drug for neurodegenerative and inflammatory bowel diseases.

Read full article Human Body-on-Chip platform enables in vitro prediction of drug behaviors in humans.

Posted on: January 30 2020

Leave a comment

Your email address will not be published. Required fields are marked *

No comments found.

About the author


Crohns & Colitis